SCHEMBL1044928

SCHEMBL1044928

OCCCc1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.56
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
IDO1 P14902 4/20 0.48
PNMT P11086 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
AOC3 Q16853 1/20 0.47
KCNH2 Q12809 1/20 0.47
PKM P14618 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CHRM2 P08172 1/20 0.44
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1804680 0.93 TAAR1 (0.54) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL6062588 0.91 TAAR1 (0.52) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL7037675 0.91 TAAR1 (0.52) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL5098205 0.87 TAAR1 (0.49) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL29538519 0.86 TAAR1 (0.60) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL624730 0.86 TAAR1 (0.60) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL1822278 0.83 TAAR1 (0.62) TAAR1HTR3EHTR3BHTR3AHTR3D
SCHEMBL29681348 0.83 TDP1 (0.43) TAAR1SLC6A4POLB
SCHEMBL1607140 0.83 TDP1 (0.43) TAAR1SLC6A4POLB
SCHEMBL29681353 0.83 TDP1 (0.43) TAAR1SLC6A4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0446301-B1 PREPARATION OF BIARYL COMPOUNDS EASTMAN CHEM CO (US) 1994-11-23 EP claimed
CN-119431317-A Cyanuric chloride trisubstituted amine derivative as antiviral, preparation method and application thereof 中国科学院上海药物研究所 2025-02-14 CN disclosed
CN-107141188-B Asymmetric ring opening method and application of 3-substituted oxetane 香港科技大学深圳研究院 2021-05-28 CN disclosed
EP-2841429-B1 TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES SUMITOMO CHEMICAL CO (JP) 2020-10-21 EP disclosed
EP-3040332-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-06-03 EP disclosed
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
US-10226452-B2 Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-03-12 US disclosed
EP-3443959-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN Bio-Pharm Solutions Co., Ltd. (KR) 2019-02-20 EP disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-9730448-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-15 US disclosed
EP-0687265-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP disclosed
WO-1995027720-A1 NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS DRUGS ROUSSEL UCLAF (FR) 1995-10-19 WO disclosed
EP-0676409-A1 Erythromycin derivatives, their process for preparation and their application as medicaments ROUSSEL UCLAF (FR) 1995-10-11 EP disclosed
WO-1995017185-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1995-06-29 WO disclosed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed
EP-0414686-B1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES LABORATOIRES LUCIEN (FR) 1993-09-22 EP disclosed
EP-0414686-A1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES. LUCIEN LAB (FR) 1991-03-06 EP disclosed
WO-1989004819-A1 DERIVATIVES OF TRIFLUOROMETHYL-1-TETRALINES, PREPARATION AND APPLICATION THEREOF FOR THE SYNTHESIS OF COMPOUNDS HAVING THERAPEUTIC PROPERTIES LABORATOIRES LUCIEN (FR) 1989-06-01 WO disclosed
EP-0222414-A2 Novel organic selenium compounds NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1987-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10226452-B2 Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments ASAH1, ASAH2, ACER2 TAAR1 3359/4885HTR3E 3103/4885HTR3B 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.